Browse AK2

Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion intermembrane space
Domain PF05191 Adenylate kinase
Function

Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Plays an important role in cellular energy homeostasis and in adenine nucleotide metabolism. Adenylate kinase activity is critical for regulation of the phosphate utilization and the AMP de novo biosynthesis pathways. Plays a key role in hematopoiesis.

> Gene Ontology
 
Biological Process GO:0006164 purine nucleotide biosynthetic process
GO:0006172 ADP biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009124 nucleoside monophosphate biosynthetic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009127 purine nucleoside monophosphate biosynthetic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009133 nucleoside diphosphate biosynthetic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009136 purine nucleoside diphosphate biosynthetic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009156 ribonucleoside monophosphate biosynthetic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009168 purine ribonucleoside monophosphate biosynthetic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009180 purine ribonucleoside diphosphate biosynthetic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009188 ribonucleoside diphosphate biosynthetic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009260 ribonucleotide biosynthetic process
GO:0015949 nucleobase-containing small molecule interconversion
GO:0042278 purine nucleoside metabolic process
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0046031 ADP metabolic process
GO:0046033 AMP metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046939 nucleotide phosphorylation
GO:0072522 purine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004017 adenylate kinase activity
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0019201 nucleotide kinase activity
GO:0019205 nucleobase-containing compound kinase activity
Cellular Component GO:0005743 mitochondrial inner membrane
GO:0005758 mitochondrial intermembrane space
GO:0005929 cilium
GO:0031514 motile cilium
GO:0031970 organelle envelope lumen
GO:0036126 sperm flagellum
GO:0044441 ciliary part
GO:0097223 sperm part
GO:0097226 sperm mitochondrial sheath
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
hsa00730 Thiamine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-499943: Synthesis and interconversion of nucleotide di- and triphosphates
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.22; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3380.0735
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3840.89
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3050.881
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2570.302
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.230.913
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2920.913
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0510.909
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0630.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1740.941
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2170.919
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0250.994
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0240.683
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAK2
Nameadenylate kinase 2
Aliases ADK2; AK 2; ATP-AMP transphosphorylase 2; adenylate kinase isoenzyme 2, mitochondrial; Adenylate kinase 2, m ......
Chromosomal Location1p35.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AK2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AK2.
ID Name Drug Type Targets #Targets
DB01717Bis(Adenosine)-5'-PentaphosphateSmall MoleculeAK1, AK2, AK83
DB03366ImidazoleSmall MoleculeAK2, CYCS, DMC1, GPHN, LTA4H, MB, MYO1E, NOS2, PIM19